Last reviewed · How we verify

remifentanil hydrochlorid

Helsinki University Central Hospital · FDA-approved active Small molecule Quality 0/100

remifentanil hydrochlorid is a Small molecule drug developed by Helsinki University Central Hospital. It is currently FDA-approved. Also known as: -Ultiva.

Remifentanil hydrochloride, marketed by Helsinki University Central Hospital, is an established anesthetic agent with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established market presence and strong patent protection. The primary risk is the potential for increased competition following the 2028 patent expiry.

At a glance

Generic nameremifentanil hydrochlorid
Also known as-Ultiva
SponsorHelsinki University Central Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about remifentanil hydrochlorid

What is remifentanil hydrochlorid?

remifentanil hydrochlorid is a Small molecule drug developed by Helsinki University Central Hospital.

Who makes remifentanil hydrochlorid?

remifentanil hydrochlorid is developed and marketed by Helsinki University Central Hospital (see full Helsinki University Central Hospital pipeline at /company/helsinki-university-central-hospital).

Is remifentanil hydrochlorid also known as anything else?

remifentanil hydrochlorid is also known as -Ultiva.

What development phase is remifentanil hydrochlorid in?

remifentanil hydrochlorid is FDA-approved (marketed).

Related